Several considerations in using traditional Chinese patent medicine for cerebral infarction
Back to article page
OriginalPaper|Updated:2021-08-27
|
Several considerations in using traditional Chinese patent medicine for cerebral infarction
Several considerations in using traditional Chinese patent medicine for cerebral infarction
中国结合医学杂志(英文版)2012年18卷第8期 页码:571-574
Affiliations:
1. Tianjin University of Traditional Chinese Medicine,Tianjin,China
2. National University of Health Sciences, Lombard,USA
3. Department of Neurology of Integrated Traditional Chinese and Western Medicine, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin,China
He, J., Kwon, Y., Li, C. et al. Several considerations in using traditional Chinese patent medicine for cerebral infarction., Chin. J. Integr. Med. 18, 571–574 (2012). https://doi.org/10.1007/s11655-012-1186-8
Jia He, Yihyun Kwon, Chao Li, et al. Several considerations in using traditional Chinese patent medicine for cerebral infarction[J]. Chinese Journal of Integrative Medicine, 2012,18(8):571-574.
He, J., Kwon, Y., Li, C. et al. Several considerations in using traditional Chinese patent medicine for cerebral infarction., Chin. J. Integr. Med. 18, 571–574 (2012). https://doi.org/10.1007/s11655-012-1186-8DOI:
Jia He, Yihyun Kwon, Chao Li, et al. Several considerations in using traditional Chinese patent medicine for cerebral infarction[J]. Chinese Journal of Integrative Medicine, 2012,18(8):571-574. DOI: 10.1007/s11655-012-1186-8.
Several considerations in using traditional Chinese patent medicine for cerebral infarction
摘要
Nowadays
a great number of traditional Chinese patent medicine (TCPM) are used more and more widely to treat cerebral infarction in China. When great attention is paid to using TCPM in the real world
several problems can be identified: ignoring the Chinese medicine (CM) therapeutic principle based on syndrome differentiation
a lack of appropriate dosage and usage based on individual patient conditions
and a shortage of evidence from randomized
double-blind
placebo-controlled clinical trials. Furthermore
in terms of evaluation of the TCPM effectiveness
few comprehensive criteria and evaluation methods recognized by the international community exist. This article addresses some opinions regarding the above mentioned problems. Prof. ZHAO Jian-guo
Abstract
Nowadays
a great number of traditional Chinese patent medicine (TCPM) are used more and more widely to treat cerebral infarction in China. When great attention is paid to using TCPM in the real world
several problems can be identified: ignoring the Chinese medicine (CM) therapeutic principle based on syndrome differentiation
a lack of appropriate dosage and usage based on individual patient conditions
and a shortage of evidence from randomized
double-blind
placebo-controlled clinical trials. Furthermore
in terms of evaluation of the TCPM effectiveness
few comprehensive criteria and evaluation methods recognized by the international community exist. This article addresses some opinions regarding the above mentioned problems. Prof. ZHAO Jian-guo
关键词
Cerebral Infarctionischemic stroketraditional Chinese patent medicine
Keywords
Cerebral Infarctionischemic stroketraditional Chinese patent medicine
references
Zhao M, Li JS, Zhang BL. The present situation of exploitation and application of Chinese patent medicine in stroke. J Emerg Tradit Chin Med (Chin) 2005;14:1216–1217.
Hou TZ. The discussion of treating stroke by TCPM based on syndrome differentiation. Lishizhen Med Mater Med Res (Chin) 2001;12:727.
Liu JP. Evidence-based medicine and individualized health care. J Chin Integr Med (Chin) 2009;7:505–508.
Luo YF, Sun YH. On the development of syndrome in traditional Chinese medicine. J Inf Tradit Chin Med (Chin) 2005;22(6):3–4.
Cai BG. The rational medication of Chinese medicine injection in ischemic stroke. J Tradit Chin Med (Chin) 2010;51:126–127.
Wang YY, Zhang BL, eds. The subject of encephalopathy in traditional Chinese medicine. 1st ed. Beijing: People’s Medical Publishing House;2007:660.
Zhang H. Discussion of rational medication of TCPM and standardized administration. Guid J Tradit Chin Med Pharm (Chin) 2009;15(10):65–66.
Xia DS, Zhang L. Analysis of rational medication of TCPM with toxicity and prevention of untoward effect. Chin J Hosp Pharm (Chin) 2010;30:2120–2122.
Xie H, Zhu LF. On safety risk factors of Chinese patent medicine. China Pharm (Chin) 2011;22:1436–1438.
Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996;46:1775–1776.
Matthews MK Jr. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998;50:1933–1994.
Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet 1998;352:36.
Zhang W, Lin XL. The rational medication in stroke by TCPM. Chin J Inf Tradit Chin Med (Chin) 2006;13(10):108–109.
Jiang JJ, Xie YM. Post-marketing re-evaluation about usage and dosage of Chinese medicine based on human population pharmacokinetics. China J Chin Mater Med (Chin) 2011;36:2811–2812.
Wu B, Liu M, Liu H, Li W, Tan S, Zhang SH, et al. Metaanalysis of traditional Chinese patent medicine for ischemic stroke. Stroke 2007;38:1973–1979.
Feigin VL. Herbal medicine in stroke-Does it have a future? Stroke 2007;38:1734–1736.
Li T. Some problems in inclusion criteria and evaluation indexes of clinical trials in traditional herbs medicine for patients with cerebral infarction. Chin J Clin Pharm Ther (Chin) 2005;12:1430–1433.
Cost-effectiveness analysis of combined Chinese medicine and Western medicine for ischemic stroke patients
A pilot study on the correlation of tongue manifestation with the site of cerebral infarction in patients with stroke
Exploring molecular mechanism underlying Chinese medicine syndrome: A study on correlation between Chinese medicine syndrome and biomarkers for ischemic stroke
The use of repeated measures analysis of variance to study the effect of phlegm-heat syndrome on neurological deficits in patients with stroke
Evaluation of the conjoint efficacy in Chinese medicine with the longitudinal latent variable linear mixed model
相关作者
暂无数据
相关机构
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center
School of Public Health, Peking University Health Science Center, Peking University
Neurology Department of Peking University First Hospital, Peking University
Neurology Department of Peking University Third Hospital, Peking University
Department of Hospital Management, Peking University Health Science Center, Peking University